Current Research

Dr. Michael Wangler

Houston, Texas

Baylor College of Medicine

A metabolomics resource for peroxisomal disorders and related conditions such as D-bifunctional protein deficiency and Rhizomelic chondrodysplasia punctata (RCDP) is being created.

Dr. Joseph Hacia

Los Angeles, California

University of Southern California

Dr. Hacia has spearheaded a multi-year project developing research resources for neurodegeneration and vision loss in peroxisomal disorders. Currently, a rat with a central nervous system defect is being developed with Dr. Hacia’s collaborator, Dr. Quilong Ying. Development of this rat will allow treatments for the brain to be tested in an animal model prior to moving to human clinical testing.

Di Wu

Rockville, Maryland

The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has hired Di Wu, a postdoctoral fellow to work on drug screening projects. GFPD is one of only 10 patient advocacy groups/nonprofit public charities in the world to be accepted into this program at NCATS

Dr. Nancy Braverman

Montreal, Quebec, Canada

McGill University

A PEX 1 mouse model is being used to (1) optimize our retinal gene therapy projects and (2) test candidate drugs for potential therapies at McGill University in Montreal, Quebec, Canada.

Jackson Labs

Bar Harbor, Maine

A mouse model will be used to provide proof of concept for gene therapy for the central nervous system.

RESEARCH

Di Wu

Dr. Nancy Braverman

Dr. Joseph Hacia

Jackson Labs

Dr. Michael Wangler

Current Research

Research collaborators and institutions

CONTACT

ADDRESS

P.O. Box 33238

Tulsa, OK 74153

CONTACT US

Email: contactus@thegfpd.org

phone: ‪(405) 418-6061‬

fax: 918-516-0227

  • Facebook
  • Twitter
  • YouTube
  • Instagram

© 2020 by The GFPD. 

 Images on this site were contributed by families and may not be used without permission.

guide-Star-Seal2018-gold-grey.png
2018-Nord-Member-grey.png
GFPD-Logo.png